FreeTheAI

STADA Launches Virustad Spray Powered by Enzymatica ColdZyme Tech in Germany

BullishMedium impact
ENZYSEK 1.91 12.35%

Healthcare company STADA has launched Virustad oral spray in Germany, utilizing ColdZyme barrier technology developed by Enzymatica AB (OMXSTO:ENZY). The product release marks an early commercial step under a 2026 partnership between the two companies, introducing the formulation to Europe's largest market for cold products.

The launch validates and monetizes Enzymatica's core ColdZyme formulation with the backing of randomized controlled trial clinical data from 2025. Because the initial commercial roll-out will scale gradually, near-term revenue expectations remain limited, with a larger financial impact projected for the 2027 cold season.

Moving forward, key metrics to watch include retail sell-through figures, rollout progress in Austria, and quantifiable revenue contributions as the distribution expands. Shares of Enzymatica AB rose 0.29% to 1.705 SEK following the update.

Key points

  • STADA introduced Virustad oral spray in Germany using Enzymatica AB barrier technology.
  • The release enters Europe's largest cold-products market under a 2026 partnership agreement.
  • The ColdZyme formulation is supported by randomized controlled trial clinical data from 2025.
  • Broader financial contribution is anticipated starting in the 2027 cold season as sales scale.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What product did STADA launch using Enzymatica technology?

STADA launched Virustad, an oral spray built on Enzymatica AB's ColdZyme barrier technology, in Germany.

When is Virustad expected to show a larger revenue impact?

While the market roll-out begins gradually, a broader financial impact is expected starting in the 2027 cold season.

What clinical evidence supports Virustad?

The ColdZyme formulation used in Virustad is backed by clinical evidence from randomized controlled trials conducted in 2025.